A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Musculoskeletal disorders
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 10 Jan 2018 Planned End Date changed from 13 Jan 2019 to 25 Dec 2018.
- 10 Jan 2018 Planned primary completion date changed from 4 Nov 2018 to 25 Dec 2018.
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.